Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00006184 · OUTCOME

Immune Response

Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma · Source last updated 2017-10-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Particpants
Interval / dispersion
Not reported
Time frame
105 days

What was measured

Immune cell depletion is defined as immunosuppression of participants T cells prior to transplant measured by cluster of differentiation 4 (CD4) counts (i.e. cells) \> 50 cells per ul.Immune T-cell depletion helps to reduce the ability to reject allogeneic cells in participants and is required for engraftment. Engraftment is the body's ability to accept donor cells.

Analysis population: This outcome measure was only pre-specified to be measured in the recipient Arm/Group.

Groups in this outcome

Recipient - Chemotherapy Group

Induction chemotherapy with fludarabine, etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone, and GCSF followed by transplant preparative regimen chemotherapy with fludarabine, cyclophosphamide, mesna, cyclosporine, and methotrexate, followed by stem cell infusion and immunization.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Recipient - Chemotherapy Group10

Reported measurements

Source class 1
Values in Particpants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Recipient - Chemotherapy Group7Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        7
denoms
  1. counts
    1. group Id
      OG000
      value
      10
    units
    Participants
description
Immune cell depletion is defined as immunosuppression of participants T cells prior to transplant measured by cluster of differentiation 4 (CD4) counts (i.e. cells) \> 50 cells per ul.Immune T-cell depletion helps to reduce the ability to reject allogeneic cells in participants and is required for engraftment. Engraftment is the body's ability to accept donor cells.
groups
  1. description
    Induction chemotherapy with fludarabine, etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone, and GCSF followed by transplant preparative regimen chemotherapy with fludarabine, cyclophosphamide, mesna, cyclosporine, and methotrexate, followed by stem cell infusion and immunization.
    id
    OG000
    title
    Recipient - Chemotherapy Group
param Type
NUMBER
population Description
This outcome measure was only pre-specified to be measured in the recipient Arm/Group.
reporting Status
POSTED
time Frame
105 days
title
Immune Response
type
PRIMARY
unit Of Measure
Particpants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice